Showing 1871-1880 of 6037 results for "".
- Researchers Take Step Closer to Developing AMD Eye Dropshttps://modernod.com/news/researchers-take-step-closer-to-developing-amd-eye-drops/2480007/Scientists at the University of Birmingham, UK, say they are one step closer to developing an eye drop that could revolutionize treatment for age-related macular degeneration (AMD), according to a university news release. Scientists led by biochemist Felicity de Cogan, PhD, from the Univer
- Retina Consultants of America Partners with Retina Consultants of Charlestonhttps://modernod.com/news/retina-consultants-of-america-partners-with-retina-consultants-of-charleston/2480539/Physician management services organizat
- Registration Now Open for Neuro-Optometric Rehabilitation Association 2024 Conferencehttps://modernod.com/news/registration-now-open-for-neuro-optometric-rehabilitation-association-association-2024-conference/2482187/Registration is now open for the Neuro-Optometric Rehabilitation Association, International (NORA) 34th annual conference, September 19-22, at the Embassy Suites by Hilton Orlando, Lake Buena Vista South in Kissimmee, Florida. The NORA annual conference is a premier event for eye care a
- Johnson & Johnson Vision Presents New Myopia, Cataract, Refractive, and Meibomian Gland Dysfunction Data at ARVO 2021https://modernod.com/news/johnson-johnson-vision-presents-new-myopia-cataract-refractive-and-meibomian-gland-dysfunction-data-at-arvo-2021/2479152/Johnson & Johnson Vision will present nearly 30 posters and papers of research data on myopia, IOL, phacoemulsification, refractive, and meibomian gland dysfunction at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting. This year’s premier vision research meet
- Zeiss Receives FDA Clearance for Epithelial Thickness Mapping for CIRRUS HD-OCThttps://modernod.com/news/zeiss-receives-fda-clearance-for-epithelial-thickness-mapping-for-cirrus-hd-oct/2476359/Zeiss announced that it has received FDA 510(k) clearance for the CIRRUS HD-OCT platform, expanding the capabilities of its Anterior Segment Premier Module to include epithelial thickness mapping (ETM). According to refractive specialist John Doane, MD, of Discover Vision Center in Kansas
- Heidelberg Engineering Showcases Technologies to Enhance the Future of Imaging Technology at ARVOhttps://modernod.com/news/heidelberg-engineering-showcases-technologies-to-enhance-the-future-of-imaging-technology-at-arvo/2482771/Heidelberg Engineering announced a portfolio of innovations aimed at redefining image quality, clinical research, and patient care in ophthalmology at ARVO. According to Heidelberg, Chameleon Imaging Research Platform is des
- Switzerland Eye Research Institute Publishes Breakthrough Case Report Using Light Exposure and Nutraceuticals for Treating Retinal Degenerationhttps://modernod.com/news/switzerland-eye-research-institute-publishes-breakthrough-case-report-using-light-exposure-and-nutraceuticals-for-treating-retinal-degeneration/2480653/Roberto Pinelli, MD, CEO of the Switzerland Eye Research Institute, announced the publication of a breakthrough paper in Archives Italiennes de Biologie. The report can be found here:
- First Patients Enrolled in 4DMT's Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMDhttps://modernod.com/news/first-patients-enrolled-in-4dmts-phase-3-clinical-trial-evaluating-4d-150-in-wet-amd/2482694/4D Molecular Therapeutics (4DMT) announced that the first patients have been enrolled across multiple sites in the 4FRONT-1 phase 3 clinical trial evaluating 4D-150 for the treatment of wet age-related macular degeneration (AMD). "This is a historic moment for 4DMT as we becom
- Clearside Biomedical Announces First Patients Enrolled in Phase 1/2a Clinical Trial of CLS-AX for the Treatment of Wet AMDhttps://modernod.com/news/clearside-biomedical-announces-first-patients-enrolled-in-phase-1-2a-clinical-trial-of-cls-ax-for-the-treatment-of-wet-amd/2478744/Clearside Biomedical announced that the first patients have been enrolled in its phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) in patients with wet age-related macular degeneration (AMD). Clinical sites, all based in the United States, are activated and curr
- Ocuphire Pharma Initiates LYNX-1 Phase 3 Study Investigating Nyxol in Night Vision Disturbanceshttps://modernod.com/news/ocuphire-pharma-initiates-lynx-1-phase-3-study-investigating-nyxol-in-night-vision-disturbances/2478713/Ocuphire Pharma announced the initiation of patient recruitment and screening in late December for its LYNX-1 phase 3 registration study evaluating the safety and efficacy of Nyxol in night vision disturbances (NVD) at multiple sites in the US. NVD, also known as dim light vision disturban